Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma

To evaluate whether the use of Bayesian adaptive randomized (AR) designs in clinical trials for glioblastoma is feasible and would allow for more efficient trials. We generated an adaptive randomization procedure that was retrospectively applied to primary patient data from four separate phase II cl...

Ausführliche Beschreibung